FIGURE 5.

Current landscape of dendritic cell and natural killer cell clinical trials. (a) About 136 clinical trials using DCs were further classified according to DC modifications, route of administration, and accompanying therapies; (b) 116 trials using NK‐cell therapies were further classified according to indication, NK cell subtype, and combination therapy regimen. mRNA: messenger RNA; GM‐CSF: granulocyte‐macrophage colony‐stimulating factor; AML/CML: acute/chronic myeloid leukemia; CAR: chimeric‐antigen receptor; CIK: cytokine‐induced killer cells; NKT: natural killer T cells